Antigen binding constructs to CD3
First Claim
Patent Images
1. A humanized antigen binding construct that comprises:
- a HCDR1 of the HCDR1 in SEQ ID NO;
86;
a HCDR2 of the HCDR2 in SEQ ID NO;
86;
a HCDR3 of the HCDR3 in SEQ ID NO;
86;
a LCDR1 of the LCDR1 in SEQ ID NO;
3;
a LCDR2 of the LCDR2 in SEQ ID NO;
3; and
a LCDR3 of the LCDR3 in SEQ ID NO;
3,wherein the humanized antigen binding construct binds specifically to CD3, andwherein the humanized antigen binding construct comprises a humanized minibody or a humanized cys-diabody,wherein the human antigen binding construct further comprises at least one of;
a LFR3 of the LFR3 in SEQ ID NO;
3;
ora HFR3 of the HFR3 in SEQ ID NO;
6 or 86.
2 Assignments
0 Petitions
Accused Products
Abstract
Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
11 Citations
9 Claims
-
1. A humanized antigen binding construct that comprises:
-
a HCDR1 of the HCDR1 in SEQ ID NO;
86;a HCDR2 of the HCDR2 in SEQ ID NO;
86;a HCDR3 of the HCDR3 in SEQ ID NO;
86;a LCDR1 of the LCDR1 in SEQ ID NO;
3;a LCDR2 of the LCDR2 in SEQ ID NO;
3; anda LCDR3 of the LCDR3 in SEQ ID NO;
3,wherein the humanized antigen binding construct binds specifically to CD3, and wherein the humanized antigen binding construct comprises a humanized minibody or a humanized cys-diabody, wherein the human antigen binding construct further comprises at least one of; a LFR3 of the LFR3 in SEQ ID NO;
3;
ora HFR3 of the HFR3 in SEQ ID NO;
6 or 86. - View Dependent Claims (2, 5, 6, 7)
-
-
3. A humanized OKT3 minibody that binds to CD3, the humanized minibody comprising a polypeptide that comprises:
-
a single-chain variable fragment (scFv) that binds to CD3, the scFv comprising a variable heavy (VH) domain linked a variable light (VL) domain, wherein the scFv comprises a LFR3 of the LFR3 in SEQ ID NO;
3, or a HFR3 of the HFR3 in SEQ ID NO;
6 or 86, or both;a hinge; and a human IgG CH3 sequence, a HCDR1 of the HCDR1 in SEQ ID NO;
6 or 86;a HCDR2 of the HCDR2 in SEQ ID NO;
6 or 86;a HCDR3 of the HCDR3 in SEQ ID NO;
6 or 86;a LCDR1 of the LCDR1 in SEQ ID NO;
3;a LCDR2 of the LCDR2 in SEQ ID NO;
3; anda LCDR3 of the LCDR3 in SEQ ID NO;
3. - View Dependent Claims (4)
-
-
8. A humanized minibody that binds to CD3, wherein the humanized minibody comprises:
a polypeptide that comprises; a single-chain variable fragment (scFv) that binds to CD3, the scFv comprising a variable heavy (VH) domain linked to a variable light (VL) domain, wherein the scFv comprises a LFR3 of the LFR3 in SEQ ID NO;
3, or a HFR3 of the HFR3 in SEQ ID NO;
6 or 86, or both;a hinge; a human IgG CH3 sequence; a HCDR1 of the HCDR1 in SEQ ID NO;
6 or 86;a HCDR2 of the HCDR2 in SEQ ID NO;
6 or 86;a HCDR3 of the HCDR3 in SEQ ID NO;
6 or 86;a LCDR1 of the LCDR1 in SEQ ID NO;
3;a LCDR2 of the LCDR2 in SEQ ID NO;
3; anda LCDR3 of the LCDR3 in SEQ ID NO;
3.
-
9. A humanized minibody that binds to CD3, wherein the humanized minibody comprises:
-
a polypeptide that comprises; a single-chain variable fragment (scFv) that binds to CD3, the scFv comprising a variable heavy (VH) domain linked to a variable light (VL) domain, wherein the scFv comprises a LFR3 of the LFR3 in SEQ ID NO;
3, or a HFR3 of the HFR3 in SEQ ID NO;
6 or 86, or both;a hinge; a human IgG CH3 sequence; a HCDR1 of the HCDR1 in SEQ ID NO;
6 or 86;a HCDR2 of the HCDR2 in SEQ ID NO;
6 or 86;a HCDR3 of the HCDR3 in SEQID NO;
6 or 86;a LCDR1 of the LCDR1 in SEQ ID NO;
3;a LCDR2 of the LCDR2 in SEQ ID NO;
3;a LCDR3 of the LCDR3 in SEQ ID NO;
3, anda detectable marker selected from the group consisting of a radioactive substance, a dye, a contrast agent, a fluorescent compound, a bioluminescent compound, an enzyme, an enhancing agent, or a nanoparticle.
-
Specification